Risk factors

What each company says could go wrong in its 10-K, and what changed since last year: the risks added, dropped and rewritten.

7,686 annual reports · 4,011 companies

Readings are automated and can be wrong; check the filing for the exact wording.

Older filings

Page 77 of 641 · 7,686 filings

  • Virginia National Bankshares (VABK) FY2025 10-K risk factors
    35 risks2 new2 dropped5 reworded

    The bank added risks concerning third-party AI deployment and retailer data breaches affecting card issuance. Macro banking panic and specific CFPB concerns were dropped.

    Filed Mar 27, 2026
  • Verde Clean Fuels (VGAS) FY2025 10-K risk factors
    71 risks8 new10 dropped22 reworded

    Suspension of the Permian Basin Project highlights a strategic shift toward capital-lite technology deployment and operational restructuring amid rising natural gas demand.

    Filed Mar 27, 2026
  • Vera Bradley (VRA) FY2026 10-K risk factors
    43 risks5 new3 dropped7 reworded

    Vera Bradley refocused its turnaround strategy around Project Sunshine, closing more underperforming stores and dropping Pura Vida distribution details. Shareholder activism and AI risks emerged as new operational concerns.

    Filed Mar 27, 2026
  • Acumen Pharmaceuticals (ABOS) FY2025 10-K risk factors
    77 risks2 new3 dropped10 reworded

    Going concern doubt added due to recurring operating losses requiring additional funding. Share issuances and institutional agreements added to stock sale risks. Regulatory and clinical trial uncertainties for lead Alzheimer's candidate sabirnetug remain central.

    Filed Mar 26, 2026
  • Actuate Therapeutics (ACTU) FY2025 10-K risk factors
    45 risks3 new41 dropped19 reworded

    Actuate Therapeutics discloses cash runway only extending to July 2026 for its sole drug candidate, elraglusib. Reliance on a single drug substance manufacturer in China creates geopolitical supply chain risks.

    Filed Mar 26, 2026
  • Argan (AGX) FY2026 10-K risk factors
    38 risks10 new13 dropped25 reworded

    Power results now emphasize project timing, cost estimates, fixed-price exposure, and customer concentration, including 80.1% of Fiscal 2026 revenue.

    Filed Mar 26, 2026
  • AmpliTech Group (AMPGZ) FY2025 10-K risk factors
    44 risks8 new2 dropped9 reworded

    Customer concentration intensified with one client accounting for 42.86% of 2025 sales compared to 13.97% in 2024. Accumulated deficit expanded to $28.02 million after recording a $7.01 million net loss in 2025. Multiple new risks were added regarding the speculative nature, expiration dates, and irrevocability of Series A and B Rights offerings.

    Filed Mar 26, 2026
  • Abercrombie & Fitch (ANF) FY2026 10-K risk factors
    25 risks3 new7 dropped11 reworded

    Abercrombie & Fitch added specific risks regarding artificial intelligence deployment and refined existing international and tariff exposures.

    Filed Mar 26, 2026
  • Apex Treasury (APXT) FY2025 10-K risk factors
    67 risks

    Apex Treasury Corp is a newly formed blank check company facing typical SPAC risks centered on completing a business combination.

    Filed Mar 26, 2026
  • BioRestorative Therapies (BRTX) FY2025 10-K risk factors
    55 risks5 new1 dropped6 reworded

    Company faces Nasdaq delisting threat after shares dropped to $0.33, and key executive employment agreements expired in March 2026 without extension.

    Filed Mar 26, 2026
  • BTCS (BTCS) FY2025 10-K risk factors
    175 risks

    ETH concentration, Ethereum protocol changes, and digital-asset volatility dominate the risk profile.

    Filed Mar 26, 2026
  • BUDA Juice (BUDA) FY2025 10-K risk factors
    43 risks

    Buda Juice relies heavily on a single customer generating up to 97% of net sales. The business requires strict cold chain logistics and fresh citrus from Mexico and Arizona. Operations depend on a single Texas production facility and third-party retailers.

    Filed Mar 26, 2026

Companies covered

4,011 companies

371 more under A